Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind controlled study of lyophilized recombinant tuberculosis vaccine (AEC/BC02) in adults with latent Mycobacterium tuberculosis infection
CTR20220240Phase 2Suspended
- Sponsor
- Anhui Zhifei Longcom Biopharmaceutical
- Start
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AEC/BC02 in Tuberculosis (TB) (2 arms), sponsored by Anhui Zhifei Longcom Biopharmaceutical. Started Feb 2022; status: suspended.
02
Drugs
AEC/BC02
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on CTR20220240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220240.